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Hepatocellular carcinoma(HCC)isoneofthemostfrequentsolidtumorsworldwide,withlimitedtreatmentoptionsandadismal
prognosis. Thus, there is a strong need to expand the basic and translational research on this deadly disease in order to improve the
prognosis of HCC patients. Although the etiologic factors responsible for HCC development have been identiﬁed, the molecular
pathogenesisoflivercancerremainspoorlyunderstood.RecentevidencehasshownthefrequentdownregulationofRasassociation
domain family (RASSF) proteins both in the early and late stages of hepatocarcinogenesis. Here, we summarize the data available
on the pathogenetic role of inactivation of RASSF proteins in liver cancer, the molecular mechanisms responsible for suppression
of RASSF proteins in HCC, and the possible clinical implications arising from these discoveries. Altogether, the data indicate that
inactivation of the RASSF1A tumor suppressor is ubiquitous in human liver cancer, while downregulation of RASSF2 and RASSF5
proteinsislimitedtospeciﬁcHCCsubsets.Also,thepresentﬁndingsspeakinfavouroftherapeuticstrategiesaimedatreexpressing
RASSF1A, RASSF2,a n dRASSF5 genes and/or inactivating the RASSF cellular inhibitors for the treatment of human liver cancer.
1.Introduction
Hepatocellular carcinoma (HCC) is one of the most frequent
tumors, with 0.25-1 million of newly diagnosed cases each
year worldwide [1–3]. HCC burden is not distributed evenly
throughout the world. Indeed, more than 80% of HCC cases
occur in sub-Saharan Africa and Eastern Asia, whereas a
much lower HCC incidence characterizes North and South
America, Northern Europe, and Oceania [1–3]. Nonetheless,
HCC frequency is rapidly growing in low-rate areas as
well. In the latter geographic areas, such a rise in HCC
occurrenceistheresultofacombinationoffactors,including
an increasing incidence of cirrhosis caused by alcohol intake,
hepatitis C virus (HCV) and hepatitis B (HBV) chronic
infection, as well as a general improvement in survival
among cirrhosis patients, who are then at risk of developing
HCC [1–3]. Furthermore, the rapidly growing number of
cryptogenic cirrhosis and HCC cases might be due to a
severe form of nonalcoholic fatty liver disease, namely, the
nonalcoholic steatohepatitis (NASH) [2].
HCC is a rapidly lethal disease, with an average life
expectancy of about 6 months from the time of the
diagnosis [1–3]. Like most other solid tumors, surgery plays
a fundamental role in its treatment. Surgical resection, local
ablation therapies, and liver transplantation are regarded as
potentially curative treatment modalities for HCC. However,
these therapeutic approaches can be applied only to a limited
number of HCC patients since the diagnosis is most often
done in the late stages of the disease [1–3]. Furthermore,
therapies with pharmacological agents or alternative strate-
gies do not substantially improve the prognosis of patients
in which HCC is unresectable [1–3]. Targeted therapies are
an innovative and emerging tool to selectively kill cancer
cells while sparing the normal, unaﬀected tissue and thus
might be useful for the treatment of human HCC. The
eﬀectiveness of targeted therapies against HCC has been
recently envisaged by the signiﬁcantly higher survival length
of patients treated with the multikinase inhibitor Sorafenib
compared with that of patients treated with placebo [4].
However, the increased life expectancy of Sorafenib-treated2 Molecular Biology International
patients is limited to about three months, implying that
Sorafenib alone cannot substantially modify the prognosis
of patients with advanced HCC [4]. This emphasizes the
need to investigate the contribution of diﬀerent signaling
pathways to tumor development and progression in human
HCC in order to identify novel prognostic markers and
molecular targets for its early diagnosis, chemoprevention,
and treatment.
Althoughepidemiologicstudieshaveidentiﬁedthemajor
risk factors, the molecular pathogenesis of HCC remains
largely unknown. It is presumed that development and pro-
gression of HCC are the consequence of cumulative genetic
and epigenetic events, similar to those described in other
solidtumors[5].Amongthemostfrequentlyinvolvedtumor
suppressor genes in HCCs are pRb, p53, M6P/IGF2 receptor,
and E-cadherin [2, 5]. Oncogenic activation of c-Myc, Cyclin
D1,a n dβ-catenin genes has also been detected in various
subsets of HCC [2, 5]. Importantly, unrestrained activa-
tion of the Ras/mitogen-activated protein kinase (MAPK)
pathway seems to play a major role both in liver malignant
transformation and tumor progression [6]. Ras proteins
are members of a family of small-guanosine-triphosphate-
(GTP-) regulated molecular switches for signaling pathways
that modulate cell growth, survival, and migration [7, 8].
Once activated, Ras induces the protein kinase activity of
RAF kinase. Raf phosphorylates and activates MAPK kinase
kinase (MEK), which subsequently phosphorylates and acti-
vates extracellular signal-regulated kinase (ERK), ultimately
leading to the upregulation of downstream targets involved
in cell proliferation, survival, migration, and invasion [7, 8].
Recent studies have shown that Ras/MAPK pathway is
upregulated by multiple factors in HCC in the absence of
Ras mutations, including downregulation of the Ras GTPase
activating proteins, loss of the ERK inhibitor dual speciﬁcity
phosphatase 1 (DUSP1), and inactivation of members of the
Ras association domain family (RASSF) proteins [6, 9, 10].
Thus, it is plausible to believe that downregulation of cellular
inhibitors of Ras may be a key and alternative mechanism
leading to the propagation of the Ras signaling in a context
of wild-type Ras in human HCC.
2. RASSFProteinsStatusin HumanHCC
Due to the widely recognized tumor suppressive role of
RASSF1A in carcinogenesis [11–15], numerous studies have
investigated its levels in human liver cancer and related
them to the clinicopathological parameters. RASSF1A was
found to be frequently and progressively downregulated in
nontumorous surrounding livers, dysplastic nodules, and
HCC when compared with normal (disease-free) livers, with
the lowest levels being detected in the tumors. In most
investigations, reduced levels of RASSF1A were found to
be ubiquitous in HCC regardless of the etiologic factors
associated with tumor development (hepatitis B or C
chronic infection, alcohol consumption, exposure to food
contaminated by aﬂatoxin B1, etc.), strongly suggesting that
universal inactivation of RASSF1A in liver cancer is required
for hepatocarcinogenesis [6, 16–22]. Of note, it has been
shown [23] that inactivation of RASSF1A gene by promoter
hypermethylation is already a frequent event in liver ﬁbrosis
and cirrhosis, conditions that often precede the development
of HCC, but not in hepatocellular adenoma (HCA). Thus,
the latter study suggests that RASSF1A hypermethylation
occursearlyduringhepatocarcinogenesisandcouldbeuseful
as a marker to help discriminating between HCA and HCC
[23]. Furthermore, a recent report indicates that reduced
RASSF1A protein expression is related to TNM stage, alpha-
fetoprotein levels, and the presence of metastasis, portal
vein emboli, capsularinﬁltration, and multiple tumor nodes,
implying thatassessmentofRASSF1Alevelsmightbehelpful
also for prognosis prediction in human HCC [24].
Diﬀerent from RASSF1A, the other main RASSF1 iso-
form (RASSF1C) was found to be expressed at similar levels
in normal livers, HCC, and corresponding nontumorous
surrounding livers [6]. As concerns RASSF2, its downreg-
ulation was detected only at tumor stage and was closely
associated with elevated serum alpha-fetoprotein level, but
not signiﬁcantly with clinical stage and hepatic ﬁbrosis [25,
26]. Levels of the main isoforms of RASSF5 (also known as
novel Ras eﬀector 1 or NORE1) were also investigated in
HCC. The analysis of a large panel of HCC samples showed
that NORE1A levels were signiﬁcantly lower in liver tumors
characterized by a poorer outcome (as deﬁned by a patients’
length of survival shorter than 3 years after partial liver
resection)whencomparedwithHCCwithabetterprognosis
(survival longer than 3 years) [6]. Thus, downregulation of
NORE1A seems to be involved in liver tumor progression
and biologic aggressiveness. Low levels of the other RASSF5
isoform, NORE1B, were also described in about 60% of
the investigated HCC [27]. In the latter tumor collection,
downregulation of the NORE1B gene did not correlate with
tumor grade or stage or the etiology of the disease [27].
Based on this body evidence, it is tempting to speculate
that NORE1A and NORE1B may possess distinct biologic
activities in liver (cancer) cells.
3. Regulation of Expressionand Activity
of RASSF Proteins
RASSF1A levels and activity are presumably regulated
by numerous and complex mechanisms in HCC. These
mechanisms include epigenetic silencing of the gene and
posttranslational modiﬁcations of the protein, which aﬀect
RASSF1A stability and half-life. In accordance with a pio-
neering study on lung cancer and several cancer-derived cell
lines, including the HepG2 hepatoma cells [28], epigenetic
RASSF1A suppression by hypermethylation of its promoter
has been suggested as the main mechanism contribut-
ing to RASSF1A downregulation in several cancer types,
including HCC [6, 11–24]. In the latter disease, promoter
hypermethylation of RASSF1A gene was shown to occur
both in nonneoplastic surrounding livers and HCC, with
higher degree of methylation being detected at tumor stage
[6, 16–24]. In particular, an intriguing study showed that,
in the hepatitic liver (aﬀected by chronic hepatitis and/or
cirrhosis, dysplastic nodules, or HCC), the RASSF1A geneMolecular Biology International 3
promoter was extensively methylated, with a methylation
degree that increased from regenerative conditions (cirrho-
sis) to dysplastic nodules, to HCC [21]. Of note, the level
of methylation at RASSF1A promoter gradually increased
by ageing in the nondiseased liver as well [21]. These
data suggest the existence of an age-related phenomenon
leading to the development and expansion of an epigeneti-
cally methylated hepatocyte subpopulation, which might be
connected to hepatocarcinogenesis. In another investigation,
the RASSF1A gene exhibited a weak but clearly detectable
methylation signal in normal liver tissue and focal nodular
hyperplasia specimens in 57% and 70% of cases, respectively,
using sensitive qualitative assay conditions [20]. By using
a stringent threshold, none of the normal tissue or focal
nodular hyperplasia specimens was methylation-positive,
whereas 85% of the hepatocellular carcinoma biopsies were
still positive for RASSF1A gene hypermethylation [20].
Furthermore, RASSF1A methylation degree possessed the
highest discriminatory power between HCC and nonma-
lignant livers [20]. Although the number of investigated
specimens was limited, this investigation strongly suggests
the use of quantitative real-time PCR-based assays for the
assessment of RASSF1A promoter methylation status, which
might be highly helpful for the discrimination between
frankly malignant and nonmalignant liver lesions. In a large-
scale study conducted in China, it was found that RASSF1A
promoterhypermethylationprecedestheoccurrenceofother
epigenetic and genetic alterations, such as hypermethyla-
tion of p16INK4A promoter and mutations of the p53
gene [29]. Based on these data, the authors suggest that
RASSF1A could represent a potential target in preventing
malignant transformation of hepatocytes [29]. In addition,
promoter methylation of RASSF1A gene has been frequently
detected in livers aﬀected by hereditary haemochromatosis,
a predisposing condition for the development of HCC [30].
Altogether, these data substantiate the role of RASSF1A inac-
tivationbothinearlyandlatestepsoflivercarcinogenesis.Of
note, promoter hypermethylation at the RASSF1A gene CpG
island was found to be frequently associated with additional
epigenetic and genetic alterations. In mammary epithelial
cells, it has been shown that RASSF1A gene inactivation is
associated with deacetylation and lysine 9 trimethylation of
histone H3 and an impaired binding of Sp1 at the RASSF1A
promoter. These epigenetic events precede the occurrence
of DNA methylation spreading in the RASSF1A promoter
[31].Thus,thesedatasuggestthathistonemodiﬁcationsmay
trigger de novo DNA methylation of the RASSF1A promoter
in epithelial cells. Similar to that described in mammary
epithelial cells, epigenetic silencing of RASSF1A gene was
demonstrated to depend on promoter hypermethylation and
histone H3-K9 methylation in human HCC samples [32].
Furthermore, loss of heterozygosity at the lung cancer tumor
suppressor locus 3p21.3, where RASSF1A is located, was fre-
quently detected in HCC specimens in which the RASSF1A
promoter was hypermethylated [6, 33]. The two-hit mode
(promoter hypermethylation and loss of heterozygosity) of
gene inactivation has been described also for other liver
tumor suppressor genes, such as SOCS1-3 and DUSP1 [6, 9].
As concerns the relationship between RASSF1A promoter
hypermethylation and the clinicopathological parameters of
HCC patients, it has been shown that RASSF1A epigenetic
silencing is signiﬁcantly associated with the levels of DNA
adducts generated by aﬂatoxin B1 (AFB1), a mycotoxin
with hepatocarcinogenic potential produced by the fungus
A s p e r g i l l u sF l a v u s[ 16]. It is important to underline the fact
that AFB1 protumorigenic potential in the liver has been
attributed to AFB1 mutagenic properties over the p53 tumor
suppressor gene so far [34, 35]. The signiﬁcant association
between AFB1 adducts and RASSF1A epigenetic inactivation
indicates that AFB1 might initiate hepatocarcinogenesis
via additional molecular mechanisms independent of p53,
including the suppression of the RASSF1A gene.
Besides epigenetic silencing and/or genetic loss, post-
translational mechanisms such as microRNA-driven sup-
pression and ubiquitin-dependent proteolysis are also in-
volved in RASSF1A inactivation in HCC. In particular,
microRNA-602 hasbeen demonstratedtonegatively regulate
RASSF1A levels in the HepG2 liver cancer cell line [36].
Also, levels of microRNA-602 were inversely correlated with
thoseofRASSF1Ainnormallivers,HCC,andcorresponding
nontumorous surrounding livers, further supporting a role
of microRNA-602 in the downregulation of RASSF1A in
human liver cancer [36]. Another way of RASSF1A inacti-
vation has been originally described in various cell lines. In
these cells, the S-phase kinase-associated protein 2 (SKP2),
an oncogenic subunit of the Skp1-Cul1-F-box ubiquitin
ligase complex, interacts with ubiquitinates and promotes
the degradation of RASSF1A at the G1-S transition of the
cellcycle[37].TheSKP2-dependentdestructionofRASSF1A
requires phosphorylation of RASSF1A on serine-203 by the
cyclin D-cyclin-dependent kinase 4 [37]. In human HCC,
it has been found that SKP2-dependent proteosomal degra-
dation occurs mainly in tumors characterized by biological
and clinical aggressiveness [38]. Also, SKP2-driven ubiqui-
tination and RASSF1A epigenetic silencing represent two
mutually exclusive mechanisms responsible for RASSF1A
inactivation in human HCC [38]. The data obtained in
the human HCC sample collection were further substan-
tiated in vitro. Indeed, transfection of SKI human HCC
cells (expressing low SKP2 levels) with wild-type SKP2
cDNA increased the proliferation rate proportionally to
SKP2 expression, concomitantly triggering downregulation
of multiple tumor suppressor proteins, including P21WAF1,
P27KIP1,P 5 7 KIP2, P130, FOXO1, and RASSF1A [38]. The
proteosomal degradation of the aforementioned proteins
was abolished by the treatment with proteosomal inhibitors
[38]. Conversely, siRNA-induced knockdown of SKP2 led to
growthrestraintofHuH7humanHCCcells(expressinghigh
SKP2 levels), which was paralleled by increase in the levels
of P21WAF1,P 2 7 KIP1,P 5 7 KIP2, P130, FOXO1, and RASSF1A
proteins [38]. Thus, these ﬁndings suggest that the SKP2-
mediated degradation of RASSF1A plays an important role
in cell proliferation and survival. Finally, it has been found
that the connector enhancer of KSR 1 (CNK1)g e n e ,w h i c h
interacts with RASSF1A and augments RASSF1A-induced
cell death [39], is also often epigenetically silenced in human
HCC [25].4 Molecular Biology International
Altogether, the present ﬁndings indicate that multiple
mechanisms might play a role in RASSF1A inactivation in
human HCC, further substantiating the need of RASSF1A
silencing for liver cancer development and progression.
As concerns RASSF2, RASSF4, and RASSF5 isoforms
(NORE1A and NORE1B), promoter hypermethylation
seems to be the prominent mechanism responsible for their
inactivation in liver cancer [6, 25, 27]. Indeed, epigenetic
silencing of RASSF2, RASSF4,a n dRASSF5 genes was in-
versely associated with low mRNA levels of the same genes
[6, 25, 27].
4. Role of RASSF Proteinsin LiverCancer
Diﬀerent from other tumor types, the biologic role of
RASSF1A has been only minimally investigated in human
liver cancer. Some interesting hints on the functional conse-
quences of RASSF1A and NORE1A inactivation on hepato-
carcinogenesis were obtained by analyzing a large collection
of human HCC specimens [6]. In the latter samples,
HCC displayed signiﬁcantly lower levels of RASSF1A/H-Ras
complexes compared with normal livers, indicating that the
ability of RASSF1A to bind H-Ras is impaired in HCC.
In contrast, RASSF1A/H-Ras complexes were increased in
nontumorous surrounding livers, showing that RASSF1A
is eﬃciently bound to H-Ras, thus presumably inhibiting
H-Ras activity, at the preneoplastic stage. Furthermore,
RASSF1A/NORE1A complexes were found only in the sur-
rounding livers but not in the normal livers or HCC
[6]. Because RASSF1A induces apoptosis through heter-
odimerization with NORE1A [40], these data indicate that
RASSF1A-mediated cell death is abrogated in human HCC.
Since the induction of RASSF1A and NORE1A leads to
activation of MST1 and MST2 proteins [40], the levels
of activated MST1 and MST2 were assessed. MST1 and
MST2 proteins were phosphorylated in all surrounding
nonneoplastic livers in association with caspase 3 cleavage
[6]. Accordingly, protein levels of activated SEK1/MMK4-
JNK and p38MAPK were low or absent in HCCs without
MST1 and MST2 phosphorylation [6], consistent with the
notion that MST1 and MST2 are upstream inducers of JNK
and p38 MAPK proapoptotic pathways. Besides inducing
apoptosis, MST1 and MST2 are crucial regulators of the
Hippo signaling pathway. The latter is a conserved signalling
cascade involved in the regulation of organ growth in
Drosophila and vertebrates. In this cascade, MST1 and
MST2 form a kinase cascade that is able to phosphorylate
at the Ser127 residue the YAP oncoprotein, involved in
unconstrained liver growth, leading to YAP inactivation [41–
44]. The importance of the Hippo pathway in preventing
hepatocarcinogenesis is underscored by the observations
that disruption of the Hippo cascade associated with YAP
activation triggers liver cancer development in the mouse.
Indeed, liver-speciﬁc ablation of mouse WW45 (homolog of
the human SAV1) gene, an adaptor for the MST kinases, led
toincreasedliversizeandexpansionofhepaticovalcellsand,
eventually, liver cancer development [45]. A similar growth
eﬀect and the unconstrained expansion of progenitor cells in
the mouse liver resulted either from the combined deletion
of MST1 and MST2 kinases [46–48] or overexpression of
the YAP oncoprotein [49, 50] .T h u s ,d u et oi t sr o l ea sa
positive regulator of the MST1 and MST2 kinases [11–15]
and as inhibitor of MST1 and MST2 dephosphorylation
[51], RASSF1A might play a crucial role in preventing liver
malignant transformation.
In a recent investigation, transfection of the wild-type
form of RASSF1A in the QGY-7703 human HCC cell
line (expressing low levels of RASSF1A) resulted in fewer
and smaller clones, decreased xenograft tumor volume and
weight, and led to G1/S arrest both in vitro and in vivo when
comparedwithcellstransfectedwiththeemptyplasmid[52].
At the molecular level, transfection of wild-type RASSF1A
resulted in decreased protein levels of cyclin D1. In addition,
forced overexpression of wild-type RASSF1A triggered cell
growth inhibition and increase in the percentage of cells in
the sub-G1 phase following the treatment with mitomycin
[52]. A novel proapoptotic pathway connecting RASSF1A to
Bax via the Bax binding protein, modulator of apoptosis-
1 (MOAP-1), has been described [53]. In this pathway,
RASSF1A and MOAP-1 interact directly, and RASSF1A can
activate Bax via MOAP-1, thus inducing cell death [53]. Of
note, this pathway is impaired in most human liver cancer
specimens, due both to inhibition of RASSF1A [53]a n d
epigenetic silencing of MOAP-1 (Calvisi et al., unpublished
results), indicating that loss of RASSF1A-driven apoptosis
might be an important molecular event in hepatocarcino-
genesis.
Taken together, these data indicate that RASSF1A might
exertitstumorsuppressiveactivityonmalignanthepatocytes
by both inhibiting proliferation and stimulating apoptosis.
The role(s) of NORE1A and NORE1B have also been
studied in human HCC. As concerns NORE1B, a microarray
study was performed to identify its putative targets in
the HEK-293T renal cell line [53]. A series of transcrip-
tional alterations due to NORE1A induction were observed.
Among the genes that showed some of the strongest
changes in the microarray assay were eukaryotic transla-
tion elongation factor 2 (EEF2) and spermidine/spermine
N1-acetyltransferase 1 (SAT1) ,w h o s el e v e l sw e r es u p p r e s s e d
following NORE1A overexpression, and p21CIP1, which was
instead upregulated [54]. Further analysis showed that, in
human HCC samples, NORE1A gene expression directly
correlated with p21CIP1 and inversely correlated with EEF2
and SAT1 expression [54]. EEF2 is a translation factor
that mediates ribosomal translocation during peptide chain
elongation and is activated by mitogenic stimuli [55]. EEF2
is overexpressed in many tumor types and seems to play
an important role in rendering tumor cells resistant to
the translation-suppressing eﬀects of hypoxia [56]. SAT1 is
instead a spermidine kinase that plays a key function in
the regulation of the intracellular levels of polyamines [57].
Polyamines play an important role in neoplastic growth,
and polyamine synthesis inhibitors are of interest as chemo-
preventive agents [58]. Microarray analysis has been also
performed to determine the signaling proﬁle of RASSF1A
in nonsmall cell lung cancer and neuroblastoma [59].
Noticeably, although RASSF1A sequence is 50% identical toMolecular Biology International 5
that of NORE1A, the two proteins promoted quite diﬀerent
a l t e r a t i o n si ng e n ee x p r e s s i o n[ 54, 59]. Indeed, SAT1 was the
only target identiﬁed by both RASSF1A and NORE1A, thus
conﬁrming the hypothesis that the functions of NORE1A
and RASSF1A are likely to be quite distinct. Several other
upregulated targets following NORE1A overexpression that
were identiﬁed in the array have also been associated with
promotionofcelldeathandinductionofgrowthsuppression
[54]. Among them, BTG3 is a putative tumor suppressor
gene and a target of p53 [60], whereas PDCD2 has been
implicated in apoptosis and proliferation control [61]. Thus,
NORE1A promotes a number of alterations in transcription
that might be involved in the repression of transformation.
Nevertheless, the most interesting eﬀect of NORE1A that
was identiﬁed in the study was the upregulation of the
p21CIP1 tumor suppressor gene [54]. The induction of
p21CIP1 by NORE1A might explain the ability of NORE1A
to induce G1 cell cycle arrest [62], since p21CIP1 has been
shown to block the cell cycle at G1 by inhibiting cdk2
[63]. As mentioned above, the examination of a panel
of human HCC showed that loss of NORE1A expression
correlatedcloselywithdownregulationof p21CIP1 expression
[54]. These ﬁndings further substantiate the existence of
a physiologic link between NORE1A and p21CIP1 in liver
cancer. Moreover, it was demonstrated that NORE1A could
only activate p21CIP1 in a wild-type p53-harboring tumor
cell line, suggesting the requirement of a nonmutated p53
gene for the transcriptional induction of p21CIP1 mediated
by NORE1A [54]. Thus, the data indicate that NORE1A
is involved in the modulation of one of the major human
tumor suppressor pathways. This conclusion was further
supported by the observation that mutations of p53 gene and
the inactivation of NORE1A were mutually exclusive events
in human HCC [54]. The molecular mechanism(s) by which
NORE1A can modulate p53 activity remains unknown.
However, an increase of p53 in the nuclear compartment
accompanied transfection of NORE1A in HuH6 human
HCC cells in the same investigation. Thus, it is tempting to
hypothesize that NORE1A promotes the nuclear localization
of p53 via some posttranslational modiﬁcation, such as
phosphorylation or acetylation.
The role of NORE1B in liver cancer was also investigated
[64]. In hepatocyte and hepatoma cell lines, NORE1B,
NORE1A,a n dRASSF1A overexpression led to increase the
percentage of cells in G0-G1 at the expense of the S-phase
fraction [64]. Furthermore, NORE1B and RASSF1A inser-
tion in hepatocyte lines resulted in an additional increase
in the G2-M fraction, with consequent delay of cell cycle
progression and suppression of cell growth. The molecular
mechanisms whereby NORE1B reduces the cells in S-phase
fraction have not been identiﬁed, although the SARAH
domain and, to some extent, the RA domain of NORE1B
were shown to be essential for growth suppression [64].
Another important discovery was that NORE1B antagonized
c-Myc/Ha-Ras-induced transformation of embryonal cells
[64]. Of note, RASSF1A alone was unable to antagonize cell
transformation but enhanced greatly the NORE1B eﬀect,
which indicates cooperation of these genes. In accordance
with the latter ﬁnding, the authors found that the NORE1B
protein interacts closely with RASSF1A, as determined with
ﬂuorescence resonance energy transfer [64]. In further
experiments, cell cycle delay by NORE1B overexpression was
equally eﬀective in hepatocyte cell lines with wild-type or
mutant Ras, suggesting that NORE1B does not interact with
Ras in order to exert its tumor suppressive function [64].
5. RASSFProteinsinExperimental
Hepatocarcinogenesis
Few studies have investigated the status of RASSF proteins in
experimental models of hepatocarcinogenesis to date.
The DNA methylation patterns of Rassf1a gene were
investigated in the early phase of rat hepatocarcinogen-
esis induced by a choline-deﬁcient L-amino acid-deﬁned
(CDAA) diet [65]. The livers of rats fed the CDAA diet for 4
and 8 days and 3 weeks were methylated in the Rassf1a gene
promoter, while normal livers were all unmethylated. These
results indicate that gene-speciﬁc DNA methylation patterns
were found in livers of rats after short-term feeding of the
CDAA diet, suggesting that gene-speciﬁc hypermethylation
might be involved in the early phase of rat hepatocarcino-
genesis induced by the CDAA diet [65].
The role of cell-cycle-regulating proteins, including
Rassf1a, has been evaluated in preneoplastic lesions, dys-
plastic nodules, and HCC, chemically induced in genetically
susceptible Fisher 344 (F344) and resistant Brown Norway
(BN) rats [66]. Rassf1a protein levels exhibited no change
or low increase in the lesions of F344 rats and consistent
rise in dysplastic nodules and HCC of BN rats. Increase in
Cks1-SKP2 ligase and proteosomal degradation of cell cycle
regulators,includingRassf1a,occurredinF344butnotinBN
rat lesions, indicating that posttranslational modiﬁcations of
cell cycle regulators are under genetic control and contribute
to determine a phenotype susceptible to HCC [66]. Fur-
thermore, a gradual increase of Rassf1a/Nore1a/Mst1-driven
apoptosis was detected in both rat strains, with highest levels
in BN HCC, resulting in signiﬁcantly higher apoptosis in
BN than F344 HCC [67]. Taken together, these data indicate
a control of the proapoptotic Rassf1a/Nore1A pathway by
HCC susceptibility genes.
In another study, the underlying molecular events asso-
ciated with tumor-promoting activity of 2-acetylamino-
ﬂuorene (2-AAF), a complete genotoxic rat hepatocarcino-
gen, were investigated [68]. The results demonstrate that
epigenetic alterations were responsible for driving hepato-
carcinogenesis in this model. In particular, preneoplastic
and neoplastic liver lesions exhibited increased histone H3
lysine 9 and histone H3 lysine 27 trimethylation in the pro-
moter regions of Rassf1a, p16INK4a, Socs1, Cdh1,a n dCx26
t u m o rs u p p r e s s o rg e n e s ,e a r l yRassf1a and p16INK4a pro-
moter CpG island hypermethylation, and altered microRNA
expression in preneoplastic livers of rats exposed to 2-AAF
[68]. These changes were accompanied by dysregulation
of the balance between cell proliferation and apoptosis, a
fundamental protumorigenic event in hepatocarcinogenesis
[67].6 Molecular Biology International
Altogether, these studies showed the frequent inactiva-
tionofRassf1aeitheraloneorincombinationwithNore1ain
ratmodelsofhepatocarcinogenesis,implyingauniversalrole
of inactivation at least some of the RASSF proteins in liver
malignant transformation and tumor progression. Based
on these data, it appeared therefore surprising that Rassf1a
null mice were tumor-prone and spontaneously developed a
variety of cancer types, but no HCC or other liver tumors
[69]. The lack of HCC development in Rassf1a knockout
mice was unexpected and remains unclear. Presumably,
hepatocarcinogenesis is not triggered by Rassf1a inactivation
alone, but additional cellular (growth stimuli such as liver
regeneration) and molecular (oncogene overexpression, loss
ofadditionaltumorsuppressorgenes)eventsarerequiredfor
HCC development in Rassf1a knockout mice. A similar situ-
ation has been described, for instance, in Sprouty 2 (a cellular
inhibitor of the MAPK pathway) knockout mice. Indeed,
inactivation of Sprouty 2 by overexpression of its dominant
negative form in the liver via hydrodynamic transfection was
unable to induce signiﬁcant changes in hepatocytes, whereas
the coexpression of the c-Met protooncogene resulted in
accelerated hepatocarcinogenesis in Sprouty 2 deﬁcient mice
[70]. Therefore, it is plausible that additional cellular and/or
molecular stimuli might be necessary for HCC development
in Rassf1a knockout mice.
6. Concluding Remarks
A downregulation of RASSF1A, RASSF2, NORE1A, and
NORE1B proteins has been described in human liver cancer.
Inparticular,RASSF1Ainactivationisaubiquitouseventand
seems to be required for early and late steps of hepatocar-
cinogenesis, whereas silencing of NORE1A is associated with
tumor aggressiveness. Some of the molecular mechanisms
whereby RASSF1A, NORE1A, and NORE1B exert their
tumor suppressive function have been determined, but
presumably these proteins play many other roles in the
control of hepatocytes proliferation and survival. In this
regard,thestudyofthecrosstalkbetweentheRASSFproteins
and the Hippo pathway will presumably provide important
insights on liver cancer pathogenesis. A role in hepatocar-
cinogenesis might be also played by the newly discovered
members of the RASSF family, known as N-Terminal RASSF
proteins (RASSF7-RASSF10) [71], whose investigation has
just begun. The use of appropriate genetically modiﬁed
models will be highly helpful for the identiﬁcation and
dissection of the RASSF-mediated mechanisms as well as
to test therapeutic approaches aimed at reactivating RASSF
proteins and/or inactivating RASSF inhibitors, such as the
SKP2 ubiquitin ligase, for the treatment of human liver
cancer.
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